UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007203 |
|---|---|
| Receipt number | R000008392 |
| Scientific Title | A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinide - |
| Date of disclosure of the study information | 2012/02/03 |
| Last modified on | 2013/09/27 09:30:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A clinical study of combination drug against type 2 diabetes
- Glubes combination tablets for patients poorly controlled with a-GI or Glinide -
Acronym
A clinical study of combination drug against type 2 diabetes
- Glubes combination tablets for patients poorly controlled with a-GI or Glinide -
Scientific Title
A clinical study of combination drug against type 2 diabetes
- Glubes combination tablets for patients poorly controlled with a-GI or Glinide -
Scientific Title:Acronym
A clinical study of combination drug against type 2 diabetes
- Glubes combination tablets for patients poorly controlled with a-GI or Glinide -
Region
| Japan |
Condition
Condition
type2 diabetes
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Study the efficacy and safety of taking unblindedly Glubes combination tablets, combined with mitiglinide calcium hydrate and voglibose, for type 2 diabetes patients who had been taking inadequate glycemic control with a monotherapy of a-GI(voglibose, acarbose, or miglitol) or glinide(mitiglinide calcium hydrate, nateglinide) in addition to diet and exercise regimen.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Efficacy endpoints:HbA1c(the JDS), blood glucose, glycated albumin, insulin, 1.5-AG, C-peptide, free fatty acids, triglycerides, apoB48, and apoC-3. Calculate HOMA-IR and HOMA-B in order to evaluate insulin resistance and function of pancreatic beta cell at each evaluation point.
Primary endpoints:HbA1c(the JDS) at the final evaluation point of each patient.
Compare the items of efficacy endpoints and the descriptive statistical number of the changing rate at each evaluation points, to the rate at 0week with t-test.
Calculate the 6.5% achievement ratio of HbA1c at each evaluation points.
Study the efficacy of taking a-GI or each glinide drugs which had been used before this study.
Safety endpoints:Evaluate the frequency and the occurrence of adverse events during this study.
Calculate the number of events and cases on the treatments of every 4 weeks, and calculate the total number of events and cases.
Analyze the adverse events against the drug by its grade, organ, and causal relationship.
Measure the descriptive statistics of observation period(0week) and treatment period(16th week) as laboratory evidences, and find the ratio of appearance of unusual change on each test values.
Measure the transitions of values of weights and blood pressures, on every 4 weeks of treatment periods.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
0th week: Perform examination under fasting conditions at the clinic. Perform examination again after the patients, who have signed a consent form, take an agent of a-GI or Glinide, and take a meal tolerance test
16th week: Perform examination under fasting conditions at the clinic. Perform examination again after the patients, who have signed a consent form, take the Glubes combination tablets and take a meal tolerance test
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Patients poorly controlled with the monotherapy of a-GI or glinide in addition to diet and exercise regimen, and regarded as appropriate to be treated with Glubes combination tablets.
2) Patients who have 6.5% HbA1c or more.
3) Age 20<=
4) Outpatient
5) Patients who voluntarily signed to the consent form with the explanation of the significance and the objectives of this study.
Key exclusion criteria
1) Patients who are applicable to the [taboo issue] in a package insert of Glubes combination tablets.
Patients who have severe ketosis, precoma or diabetic coma or type 1 diabetes.
Patients with severe infection or severe injury.
Patients accepting surgery.
Patients with a history of hypersensitivity to any component of this drug.
Pregnant women and women suspected to be pregnant.
2) Patients whom the principal investigator and investigators decided not to be appropriate for taking Glubes combination tablets, on the point of [Special caution needed] and [side effects] in the package insert.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshihiko Sato |
Organization
Sato Internal medicine clinic
Division name
M.D
Zip code
Address
Nanpeidaichou13-1,Shibuya-ku,Tokyo Sato Bilding1F
TEL
042-352-7676
erika-yamagishi@npo-acro.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Erika Yamagishi |
Organization
NPO Advanced Clinical Research Organization
Division name
NPO Advanced Clinical Research Organization
Zip code
Address
4F Hoei Fuchu Bulding,2-10-3 Kotobukicho,Fuchu-shi,Tokyo
TEL
042-352-7676
Homepage URL
erika-yamagishi@npo-acro.jp
Sponsor or person
Institute
Advanced Clinical Research Organization
Institute
Department
Personal name
Funding Source
Organization
Advanced Clinical Research Organization
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 02 | Month | 03 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 01 | Month | 12 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 02 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 02 | Month | 02 | Day |
Last modified on
| 2013 | Year | 09 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008392
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
